Cargando…

SARS-CoV-2 Antibody and T Cell Response after a Third Vaccine Dose in Hemodialysis Patients Compared with Healthy Controls

Hemodialysis (HD) patients have an increased risk of severe SARS-CoV-2 infection. In this study, we assess the impact of a third vaccine dose (3D) on antibody levels and T cell response in HD patients and a healthy control group in a prospective cohort study consisting of 60 HD patients and 65 healt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simon, Benedikt, Rubey, Harald, Gromann, Martin, Knopf-Völkerer, Astrid, Hemedi, Boris, Zehetmayer, Sonja, Kirsch, Bernhard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145549/ https://www.ncbi.nlm.nih.gov/pubmed/35632450 http://dx.doi.org/10.3390/vaccines10050694

Ejemplares similares

SARS-CoV-2-Spike Antibody and T-Cell Responses Elicited by a Homologous Third mRNA COVID-19 Dose in Hemodialysis and Kidney Transplant Recipients
por: Panizo, Nayara, et al.
Publicado: (2022)

SARS-CoV-2 Antibody Response After a Third Dose of the BNT162b2 Vaccine in Patients Receiving Maintenance Hemodialysis or Peritoneal Dialysis
por: Bensouna, Ilias, et al.
Publicado: (2022)

Favorable Humoral Response to Third Dose of BNT162b2 in Patients Undergoing Hemodialysis
por: Kitamura, Mineaki, et al.
Publicado: (2022)

Improved Immune Response to the Third COVID-19 mRNA Vaccine Dose in Hemodialysis Patients
por: Kanai, Daisuke, et al.
Publicado: (2022)

Comparison of Humoral Response between Third and Fourth Doses of COVID-19 Vaccine in Hemodialysis Patients
por: Joo, Yoosun, et al.
Publicado: (2023)

Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
por: Ju, Bin, et al.
Publicado: (2022)

Antibody response to a third dose of SARS‐CoV‐2 vaccine in heart and lung transplant recipients
por: Alejo, Jennifer L., et al.
Publicado: (2022)

Adverse events following the first, second and third doses of a COVID-19 vaccine in hemodialysis patients
por: Pai, Mei-Fen, et al.
Publicado: (2023)

False discovery rate control in two-stage designs
por: Zehetmayer, Sonja, et al.
Publicado: (2012)

Could lysine supplementation prevent Alzheimer’s dementia? A novel hypothesis
por: Rubey, Robert N
Publicado: (2010)

Cross reactivity of spike glycoprotein induced antibody against Delta and Omicron variants before and after third SARS-CoV-2 vaccine dose in healthy and immunocompromised individuals
por: Faustini, Sian, et al.
Publicado: (2022)

Screening and Confirmatory Testing for SARS-CoV-2 Antibodies: Comparison of Health and Non-Health Workers in a Nationwide Healthcare Organization in Central Europe
por: Bartko, Johann, et al.
Publicado: (2021)

Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency
por: Nielsen, Bibi Uhre, et al.
Publicado: (2022)

Antibody Titers After a Third and Fourth SARS-CoV-2 Vaccine Dose in Bizen City, Japan
por: Kadowaki, Tomoka, et al.
Publicado: (2023)

Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
por: Ishizaka, Aya, et al.
Publicado: (2023)

A third dose SARS‑CoV‑2 BNT162b2 mRNA vaccine results in improved immune response in hemodialysis patients
por: Melin, Jan, et al.
Publicado: (2022)

Evolution of SARS-CoV-2-Neutralizing Antibodies after Two Standard Dose Vaccinations, Risk Factors for Non-Response and Effect of a Third Dose Booster Vaccination in Non-Responders on Hemodialysis: A Prospective Multi-Centre Cohort Study
por: Tillmann, Frank-Peter, et al.
Publicado: (2021)

The Slower Antibody Response in Myelofibrosis Patients after Two Doses of mRNA SARS-CoV-2 Vaccine Calls for a Third Dose
por: Fiorino, Fabio, et al.
Publicado: (2021)

A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination
por: Zhou, Taicheng, et al.
Publicado: (2022)

Prevalence of antibodies against SARS-CoV-2 in hemodialysis patients
por: Arteaga-Müller, Giovanna Yazmin, et al.
Publicado: (2021)

Factors associated with poor antibody response to third-dose SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases
por: Connolly, Caoilfhionn M, et al.
Publicado: (2022)

SARS-CoV-2 Breakthrough Infections after Third Doses Boost IgG Specific Salivary and Blood Antibodies
por: Badano, María Noel, et al.
Publicado: (2023)

Neutralizing Antibody Activity Against the B.1.617.2 (delta) Variant Before and After a Third BNT162b2 Vaccine Dose in Hemodialysis Patients
por: Benning, Louise, et al.
Publicado: (2022)

Long-term trajectories of SARS-CoV-2 neutralizing antibodies and predictive value of first dose vaccination-induced IgG-antibodies in hemodialysis patients
por: Tillmann, F. P., et al.
Publicado: (2021)

Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose
por: Angel-Korman, Avital, et al.
Publicado: (2021)

Third Dose of the BNT162b2 Vaccine Results in Sustained High Levels of Neutralizing Antibodies Against SARS-CoV-2 at 6 Months Following Vaccination in Healthy Individuals
por: Ntanasis-Stathopoulos, Ioannis, et al.
Publicado: (2022)

Third COVID-19 vaccine dose boosts neutralizing antibodies in poor responders
por: Lake, Douglas F., et al.
Publicado: (2022)

Antibody level dynamics until after the third dose of COVID-19 vaccination
por: Asahi, Nanae, et al.
Publicado: (2023)

An omnibus test for the global null hypothesis
por: Futschik, Andreas, et al.
Publicado: (2018)

Study protocol for a randomised controlled trial to evaluate the effectiveness of a serious game targeting interpersonal emotion regulation in early adolescents
por: Mittmann, Gloria, et al.
Publicado: (2021)

Impact of adaptive filtering on power and false discovery rate in RNA-seq experiments
por: Zehetmayer, Sonja, et al.
Publicado: (2022)

Online control of the False Discovery Rate in group-sequential platform trials
por: Zehetmayer, Sonja, et al.
Publicado: (2022)

Antibody Response in Healthcare Workers before and after the Third Dose of Anti-SARS-CoV-2 Vaccine: A Pilot Study
por: Panico, Alessandra, et al.
Publicado: (2022)

Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in liver transplant recipients
por: Herrán, Aitor Odriozola, et al.
Publicado: (2022)

Strong Decay of SARS-CoV-2 Spike Antibodies after 2 BNT162b2 Vaccine Doses and High Antibody Response to a Third Dose in Nursing Home Residents
por: Blain, Hubert, et al.
Publicado: (2022)

Antibody titers against SARS-CoV-2 spike protein 6 months after a third BNT162b2 vaccine in chronic hemodialysis patients
por: El Haggan, Wael, et al.
Publicado: (2022)

A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses
por: Pettini, Elena, et al.
Publicado: (2022)

654: A THIRD DOSE OF SARS-COV-2 VACCINE YIELDS HIGH ANTIBODY LEVELS COMPARED TO TWO DOSE VACCINATION SCHEDULE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
por: Quan, Joshua, et al.
Publicado: (2022)

Evaluation of risk factor management of patients treated on an internal nephrology ward: a pilot study
por: Stemer, Gunar, et al.
Publicado: (2009)

Chancen und Einsatzmöglichkeiten von Telemedizin in der Hals‑, Nasen- und Ohrenheilkunde bei der Bekämpfung von SARS-COV-2: Narratives Review
por: Hagge, Daniel, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_d28e42ntb25p0h0d549iigb3ms